Lundbeck Highlights Vyepti Potential, But Company's 2021 Outlook Cautious

Long-Acting Migraine Therapy Awaiting Approval In 12 Markets

04 Feb 2021

• By John Davis

Lundbeck is focused on the global launch of its new migraine therapy Vyepti in the coming years, and the development of additional indications, as its reported a 4% increase in revenues in 2020 which were within its pre-pandemic guidance.

migraine word on wood — • Source: Shutterstock

H. Lundbeck A/S achieved a lot in 2020 with its newest product, the migraine preventive therapy, Vyepti (eptinezumab-jjmr), administered by quarterly intravenous infusion, despite the COVID-19 pandemic, reported company president and CEO Deborah Dunsire.

Achievements with Vyepti included its approval in another two markets, Canada and the United Arab Emirates (UAE), and the acceptance...